• 1
    Gust ID. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine 1992;10(Suppl 1):S5658.
  • 2
    Buisson Y, Roué R, Molinié C, Laverdan C. Hepatitis A virus in the French army: epidemiology and prophylaxis. In: BuissonY, CourssagetP, KaneM, eds. Enterically-transmitted hepatitis viruses. La Simarre , Joué-Lès-Tours (France), 1996:7884.
  • 3
    Steffen R. Hepatitis A in travelers: the European experience. J Infect Dis 1995;171(Suppl 1):S2428.
  • 4
    André FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992;10(Suppl 1):S160168.
  • 5
    Studer S, Joller-Jemelka HI, Steffen R, Grob PJ. Prevalence of hepatitis A antibodies in Swiss travelers. Eur J Epidemiol 1993;9:5054.
  • 6
    Fry G, Kenny JV, Quinn M, et al. Prevalence of hepatitis A IgG in Irish international travelers. Irish Med J 1993;86:137138.
  • 7
    Bienzle U, Bock HL, Meister W, et al. Anti-HAV seroprevalence in German travelers and hepatitis A vaccination in immune subjects [Letter]. Lancet 1993;341:1028.
  • 8
    Larouzé B, Gaudebout C, Mercier E, et al. Infection with hepatitis A and B viruses in French volunteers working in tropical Africa. Am J Epidemiol 1987;126:3137.
  • 9
    Van Damme P, Matheï C, Thoelens S, et al. Single dose of inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994;44:435441.
  • 10
    Van Doorslaer E, Tormans G, Van Damme P. Cost-effectiveness analysis of vaccination against hepatitis A in travellers. J Med Virol 1994;44:463469.